Clinical ResearchInterventional CardiologyPaclitaxel- Versus Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease
Interventional Cardiology
Under an Elsevier user license
open archive
Key Words
coronary artery disease
drug-eluting stents
left main coronary artery
paclitaxel
restenosis
sirolimus
Abbreviations and Acronyms
BMS
bare-metal stent(s)
CABG
aorto-coronary artery bypass graft surgery
CI
confidence interval
CK
creatine kinase
DES
drug-eluting stent(s)
MI
myocardial infarction
PCI
percutaneous coronary intervention
PES
paclitaxel-eluting stents(s)
RR
relative risk
SES
sirolimus-eluting stent(s)
TLR
target lesion revascularization
uLMCA
unprotected left main coronary artery
Cited by (0)
The ISAR-LEFT-MAIN study was supported in part by an unrestricted grant from Cordis. Dr. Mehilli has received lecture fees from Lilly Germany and Daiichi Sankyo. Dr. Kastrati has received lecture fees from Bristol-Myers Squibb, Cordis, GlaxoSmithKline, Lilly Germany, Medtronic, Novartis, and Sanofi-Aventis. Dr. Seyfarth has received lecture fees from Bristol-Myers Squibb, Lilly Germany, and Sanofi-Aventis. Dr. Byrne acknowledges receipt of a research fellowship in atherothrombosis from the European Society of Cardiology.
Copyright © 2009 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.